# Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

> **NCT00062101** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 80 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** celecoxib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00062101
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2006-01
- **Final completion:** —
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062101, "Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00062101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*